Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenC-Hib conjugate vaccine
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The MenC-Hib conjugate vaccine is an investigational combination vaccine developed by Chiron (now part of GSK) designed to provide simultaneous protection against Neisseria meningitidis serogroup C and Haemophilus influenzae type b (Hib). The vaccine utilizes Chiron's CRM197-based conjugate technology, where the capsular polysaccharides of MenC and Hib (polyribosylribitol phosphate) are covalently linked to the non-toxic mutant of diphtheria toxin, CRM197, to enhance immunogenicity, particularly in infants. It was evaluated in Phase I/II clinical trials in healthy adults to compare its safety and immunogenicity against the separate administration of the licensed vaccines Menjugate and VaxemHib. Although the individual components are approved, this specific combined formulation did not proceed to global regulatory approval as a standalone product.
- Other names
- meningococcal C–Haemophilus influenzae type b conjugate vaccineMenC-Hib vaccinecombined MenC-Hib vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on MenC-Hib conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenC-Hib conjugate vaccine.